Faeth Therapeutics, Inc.
FTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829802
No open-market purchases or sales by Faeth Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $333.8M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Faeth Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 24 | 20 | −4 |
| Shares | 2.36M | 1.93M | −434.7K (−18.4%) |
| Value | $1.16M | $760.2K | −$397.7K (−34.3%) |
New holders (2)
Institutions that held Faeth Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Barclays PLC | 2,558 | $1.01K | 0.00% |
| Citigroup Inc | 124 | $49 | 0.00% |
Sold out (6)
Institutions that held Faeth Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| XTX Topco Ltd | 62,903 | $30.8K |
| Citadel Advisors LLC | 57,717 | $28.3K |
| Bridgeway Capital Management, LLC | 47,900 | $23.5K |
| Susquehanna International Group, LLP | 38,051 | $18.6K |
| Deuterium Capital Management, LLC | 11,000 | $5.39K |
| HRT Financial LP | 11,600 | $5.00K |